ZA200604983B - Pharmaceutical composition which can be used in particular as an antiviral, antibacterial and for stimulating the immune defences - Google Patents
Pharmaceutical composition which can be used in particular as an antiviral, antibacterial and for stimulating the immune defences Download PDFInfo
- Publication number
- ZA200604983B ZA200604983B ZA200604983A ZA200604983A ZA200604983B ZA 200604983 B ZA200604983 B ZA 200604983B ZA 200604983 A ZA200604983 A ZA 200604983A ZA 200604983 A ZA200604983 A ZA 200604983A ZA 200604983 B ZA200604983 B ZA 200604983B
- Authority
- ZA
- South Africa
- Prior art keywords
- extract
- composition according
- extracts
- cyathea
- fagara
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 10
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 8
- 230000000840 anti-viral effect Effects 0.000 title claims abstract description 7
- 230000004936 stimulating effect Effects 0.000 title description 3
- 239000000284 extract Substances 0.000 claims abstract description 64
- 239000000203 mixture Substances 0.000 claims abstract description 37
- 241000196324 Embryophyta Species 0.000 claims description 34
- 241000723185 Cyathea Species 0.000 claims description 13
- 239000000463 material Substances 0.000 claims description 13
- 208000030507 AIDS Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 241000044532 Paspalum conjugatum Species 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 241000894007 species Species 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 5
- 229940121375 antifungal agent Drugs 0.000 claims description 4
- 235000008216 herbs Nutrition 0.000 claims description 4
- 241001330453 Paspalum Species 0.000 claims description 3
- 230000000843 anti-fungal effect Effects 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 2
- 241000209504 Poaceae Species 0.000 abstract 1
- 241001093501 Rutaceae Species 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 description 14
- 239000007788 liquid Substances 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 241000725303 Human immunodeficiency virus Species 0.000 description 7
- 210000000987 immune system Anatomy 0.000 description 7
- 229940088710 antibiotic agent Drugs 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 208000035143 Bacterial infection Diseases 0.000 description 3
- 239000001828 Gelatine Substances 0.000 description 3
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 208000037357 HIV infectious disease Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- YIWGJFPJRAEKMK-UHFFFAOYSA-N 1-(2H-benzotriazol-5-yl)-3-methyl-8-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carbonyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione Chemical compound CN1C(=O)N(c2ccc3n[nH]nc3c2)C2(CCN(CC2)C(=O)c2cnc(NCc3cccc(OC(F)(F)F)c3)nc2)C1=O YIWGJFPJRAEKMK-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 241001410432 Cyathea manniana Species 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- PDLGMYVCPJOYAR-DKIMLUQUSA-N Glu-Leu-Phe-Ala Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](C)C(O)=O)CC1=CC=CC=C1 PDLGMYVCPJOYAR-DKIMLUQUSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012675 alcoholic extract Substances 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- PZZYQPZGQPZBDN-UHFFFAOYSA-N aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 description 1
- 229910000323 aluminium silicate Inorganic materials 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003356 anti-rheumatic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 239000000399 hydroalcoholic extract Substances 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007119 pathological manifestation Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 244000000000 soil microbiome Species 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Immunology (AREA)
- Botany (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to a pharmaceutical composition comprising an extract of: at least one member of the Gramineae family, at least one member of the Rutaceae family and at least one pteridophyte. In addition to having an antiviral and antibacterial activity, the inventive composition can also be used to stimulate immune defences.
Description
Pharmaceutical composition which can be used in particular as an antiviral, antibacterial and for stimulating the immune defences
The present invention relates to a pharmaceutical composition containing, as active ingredient, the mixture of at least one extract of at least one gramineous plant, an extract of at least one rutaceous herb, and an extract of at least one : pteridophyte. This composition is intended in particular to stimulate the immune defences and can be used as an antiviral and as an antibacterial.
The immune system comprises a collection of specialist cells that are governed by numerous control mechanisms which ensure their renewal, their activation, and their differentiation, which are essential for a normal level of immunocompetence. The role of the immune system is to recognize self and not self in order to eliminate pathogenic agents and spontaneous tumours. Any cellular depletion, any immune disorder or any functional deficit is capable of encouraging the survival of pathological manifestations characterized by microbial and viral attacks.
Blood tissue constitutes one of the active elements of the immune system.
The types of cells involved in immune defence include T lymphocytes, B lymphocytes, K cells, macrophages and antibodies. Thanks to its immune system, healthy blood tissue can combat attacks from outside using the resources placed at its disposal. Nevertheless, certain cells involved in the immune system such as T lymphocytes can themselves be subject to attack or even destruction by viruses such as HIV.
These attacks manifest themselves by suppressing the immune defences, leading to a lowering of resistances to pathogenic agents and in particular an increase in the incidence of certain diseases called AIDS opportunistic diseases.
AIDS opportunistic diseases have various origins. Bacterial and fungal infections are the most common. Treatments with antifungals and antibacterials are the ones most used to fight these opportunistic diseases.
Antibiotics are for the most part natural substances originating from microscopic fungi or soil bacteria. The arrival of penicillin, then of streptomycin in the 40's started the era of antibiotics. Their use has enabled millions of lives to be saved. The appearance of resistance to antibiotics is today recognised as a major public health problem. Muitiresistance is due to the fact that these pathogenic agents are regularly subjected to the action of several families of antibiotics. : In the fight against resistances, it has become a matter of urgency to develop novel approaches ranging from molecular biology to strategic research, intended to systematically explore the resources of nature, more particularly of antibiotics originating from plants.
One of the aims of the invention is therefore to propose a novel pharmaceutical composition which acts not only as an immunoregulator stimulating not only more particularly the immune system, but also able to be used as an antibacterial and as an antiviral.
Unexpectedly, it was found that the administration by oral route (per os) of an effective quantity of at least one extract of at least one gramineous plant, plus an extract of at least one rutaceous herb, plus an extract of at least one pteridophyte allows stimulation of the immune defences, more particularly the blood immune defences, when the immune system is attacked by viruses and more particularly by the AIDS virus, by bacteria and fungi. ~~ The administration by the oral route of at least one extract of at least one gramineous plant, plus the extract of at least one rutaceous herb, plus the extract of at least one pteridophyte is particularly effective in the stimulation of the immune defences when these are weakened by infection by the AIDS virus and opportunistic diseases in general.
Therefore a subject of the invention is a pharmaceutical composition containing at least one extract of at least one gramineous plant, plus the extract of at least one rutaceous herb, plus an extract of at least one pteridophyte, intended in particular to stimulate the immune defences and particularly the immune defences of the blood tissue.
A subject of the invention is also a pharmaceutical composition containing at least one extract of at least one gramineous plant, plus an extract of at least one rutaceous herb, plus an extract of at least one pteridophyte, used to fight bacterial and viral infections, or able to be used as an antifungal. . 5 The family of the gramineous plants comprises several species. The plants ) of the gramineous plants family are above all used for cardiac affections, : contusions, sprains and dislocations. Among the genera of gramineous plants that can be used according to the invention there can be mentioned, by way of example, the paspalum genus. As plant material that can be used, there can be mentioned that originating from the conjugatum species. The leaves can be used as plant material, as can the whole plant either in the form of extracts of fresh plants or in the form of dried plant extracts.
The family of the rutaceous herbs also comprises several species. The plants of the family of rutaceous herbs are above all traditionally used for their analgesic antirheumatic properties, against cardiac palpitations and sometimes to narcotize fish in rivers.
Among the genera of rutaceous herbs that can be used according to the invention there can be mentioned, by way of example, the fagara genus. As plant material that can be used, there can be mentioned that originating from the plant species fagara heitzii. The extracts of the leaves, the bark and the roots can be used as plant material.
The family of the pteridophytes also comprises several species. The plants - — 7 “of the pteridophytes family are above all traditionally used for their gastric ulcer- oC treating properties. Among the pteridophyte genera that can be used according to the invention there can be mentioned, by way of example, the cyathea genus. As plant material that can be used there can be mentioned that originating from the plant species cyathea aethiopica, cyathea manniana. Extracts of the leaves, the stems and the roots can be used as plant material.
Any extraction method known to a person skilled in the art can be used to prepare the paspalum, fagara, and cyathea extracts which can be used according to the invention. In particular, alcoholic extracts, in particular ethanolic or also hydroalcoholic extracts, can be mentioned. Thus, in a first stage the plant material is cold-ground in an aqueous solution, in a second stage the suspended particles are eliminated from the aqueous solution originating from the first stage. In the third stage the aqueous solution originating from the second stage is sterilized. This aqueous solution corresponds to the extract. On the other hand, the first stage can advantageously be replaced by an operation of freezing the plant fragments (for example at —20°C), followed by an aqueous cold extraction incorporating the second and third stages described above. The } product of this aqueous extraction can also be lyophilized in order to obtain a dry extract (on average depending on the nature of the initial source, between 3 and ) 80 g of dry material is found per litre of aqueous extract).
An example of preparation of an extract of a gramineous plant, plus a rutaceous herb, plus pteridophyte which can be used according to the invention is given in the examples. The quantity of extract which can be used according to the invention depends on the sought effect and can therefore vary widely. To give an order of magnitude, a dry or liquid or lyophilized extract of gramineous plant can be used, more particularly paspalum conjugatum, as defined previously in a quantity representing from 0.0001% to 30 % of the total weight of the composition and preferably in a quantity representing 0.001 % to 15 % of the total weight of the composition. A dry or liquid or lyophilized extract of a rutaceous herb can be used, more particularly fagara heitzii as defined previously in a quantity representing from 0.0001% to 99 % of the total weight of the composition and preferentially in a quantity representing 0.001 % to 77 % of the total weight of the composition. A dry or liquid or lyophilized extract of pteridophytes can be used, more particularly cyathea aethiopica, as defined previously in a quantity representing from 0.0001% to 20 % of the total weight of the composition and preferentially in a quantity representing 0.001 % to 8 % of the total weight of the oo composition.
The compositions according to the invention are compositions for pharmaceutical use and can be presented in all the galenic forms normally used for oral administration. In known manner, the compositions of the invention can also contain adjuvants customary in the corresponding fields, such as hydrophilic or lipophilic gelling agents, preservatives, antioxidants, colouring materials.
Moreover, these compositions can contain hydrophilic or lipophilic active ingredients. The quantities of these adjuvants or active ingredients are those normally used in the pharmaceutical field and for example from 0.01% to 20% of the total weight of the composition.
When the compositions of the invention are intended for an application by the oral route, they can be presented in galenic forms customary in this field, such as tablets, gelatine capsules, drinkable products, in particular made up for immediate use, granules, powders, in the excipients that are customary for such an application.
A subject of the invention is also a pharmaceutical treatment method intended to stimulate the immune defences, to fight bacterial and viral infections 5 consisting of ingesting a composition containing at least one extract of at least one ) gramineous plant, plus one extract of at least one rutaceous herb, plus one extract of at least one pteridophyte as described previously.
The following examples and compositions illustrate the invention without limiting it in any way. In the compositions, the proportions indicated are in percentages by weight unless indicated otherwise.
Example 1: Preparation of a paspalum conjugatum extract.
Two hundred grams of the fresh plant are collected then mixed with 80 ml of water which is preferably, but non-limitatively, demineralized. The whole is ground and heated to approximately 10°C for 20 to 30 minutes. The ground product is then pressed in order to collect the juice which is then filtered, preferably by a non-limitative sterilizing filtration. The thus-obtained extract is stored at 4°C. It contains approximately 15 g of dry material per litre and can be lyophilized in order to obtain a dry extract. The sterilizing filtration prevents degradation of the active ingredients by the micro-organisms in the environment.
The use of water as vehicle facilitates preparation of the pharmaceutical formulations. The extract of paspalum conjugatum can also be used in the form of
Co UwextiEet. ee er ee
Example 2: Preparation of an extract of fagara heitzii.
The preparation of fagara heitzii according to the invention involves the bark in particular. Approximately one kilogram of the bark of fagara heitzii is mixed with 400 ml of water which is preferably, but non-limitatively, demineralized then ground in the mixer then heated to more than 100 °C, then cooled before extracting the juice by pressure, then filtered and sterilized preferably by a non- limitative sterilizing filtration. The thus-obtained extract is stored at 4 °C. It contains approximately 20 g of dry material per litre and can be lyophilized in order to obtain a dry extract.
Example 3: Preparation an extract of cyathea aethiopica.
The preparation of cyathea aethiopica according to the invention uses in particular all the aerial parts of the plant. Approximately 100 grams of cyathea aethiopica are mixed with 50 ml of water which is preferably, but non-limitatively, demineralized then ground in the mixer before extracting the juice by pressure, then filtered and sterilized preferably by a non limitative sterilizing filtration. The thus-obtained extract is stored at 4°C. It contains approximately 15 g of dry } 5 material per litre and can be lyophilized in order to obtain a dry extract.
The dosage of the composition according to the invention varies according : to the symptoms and treatments to be administered to patients. For an oral administration for adults, the usual dose of the composition is from 300 to 750 mg per day, preferably 500 mg per day calculated as the active components, and divided in two 250-mg morning and evening doses. This dosage allows the therapeutic effects of the composition to be observed.
The antiviral, antibacterial, antifungal pharmaceutical composition intended to stimulate the immune defences according to the invention contains at least one extract of at least one gramineous plant for example paspalum conjugatum, at least one extract of at least one rutaceous herb for example fagara heitzii, and at least one extract of at least one pteridophyte for example cyathea aethiopica and at least one solid or liquid excipient. The composition intended for oral administration is usually in the form of powder, tablets including sublingual tablets, emulsion, encapsulated preparation, granules, pills, liquid preparations including extracts and syrups. The solid or liquid excipients are generally known to persons © skilled in the art, each preparation preferably containing only one of the excipients mentioned in the example which follows.
The examples of the excipients used for the powders and granules or other preparations intended for oral administration are: lactose, starch, dextrin, calcium phosphate, calcium carbonate, natural or synthetic aluminium silicate, magnesium oxide, hydrated aluminium hydroxide, magnesium stearate, sodium bicarbonate.
The preparations mentioned more [particularly] above can be formulated by the methods conventionally. The extracts of paspalum conjugatum, fagara heitzij, cyathea aethiopica according to the invention could be used as food supplements which are useful for maintaining good health without producing any therapeutic effect. In this case, it is desirable for the preparation to be administered in the form of liquid, granules, tea, capsules or other usual forms.
Example 4: Examples of formulations illustrating the invention by way of example and non-limitatively. These formulations were obtained by simply mixing the different components.
Composition 1: Liquid preparation of the plant extracts 1- the extract of Example 1 9 % 2- the extract of Example 2 65 % : 3- the extract of Example 3 6 % 4- honey or sugar 20 %
Composition 2: Gelatine capsules or powder 1- the extract of Example 1 (lyophilized extract) 15% 2- the extract of Example 2 (lyophilized extract) 77 % 3- the extract of Example 3 (lyophilized extract) 8 %
Composition 3: Gelatine capsules or powder 1- the extract of Example 2 (lyophilized extract) 64.36 % 2- n-acetylcysteine 34.25% 3- Selenium 0.03 % 4- Zinc 0.6 % 5- tron 0.5%
TTT TTT EGopper TT TT TT oma 7- Molybdenum 0.02%
Clinical evaluation of Composition 1.
Study details:
The study was carried out in the two medical centres run by Doctor Pierre
PYEBI-OYOUBI in Gabon, with the aim of testing the effectiveness of the combination of the extracts of paspalum conjugatum, fagara heitzii and cyathea aethiopica on the HIV-AIDS diseases. An automated HIV infection screening test (VIDAS HIV DUO or VT) was carried out before and after the treatment with the combination of the extracts of three plants. The VIDAS system is based on the combined detection of the P24 antigen of HIV-1 and the anti-HIV1 and anti-HIV2 immunoglobulins G in the serum by the ELFA technique. The opportunistic diseases associated with AIDS were also evaluated before and after the treatment.
A medical appraisal is carried out before and after a treatment lasting 1 to 6 months. A complete blood count (CBC) was also carried out before and after the } 5 treatment.
The CBC or hemogram makes it possible to measure the number of : elements of each of the three categories of blood cells which are the red blood cells, white blood cells (leucocytes) and platelets. The red and white cell count consists of counting the number of cells in each category, and the white blood 10 picture to divide the white blood cells into different classes according to their characteristics. These different items of information are used, for example, to diagnose anaemia.
These examinations provide fundamental information, and they are required systematically during an appraisal, in particular when anaemia (lowering 15 of the level of red blood cells) or an infection is suspected. The results also vary depending on a number of elements including the medicines taken.
A group of twelve HIV positive people were selected for this study.
The results obtained are as follows: 20 Effect of Composition 1 on the presence of the P24 antigen of HIV-1 and the anti- © HIV! and anti -HIV2 immunoglobulins ~~ ~~ 7 7 70
Figure1 20 16 Ch £ 12 al
S 8 “Ch
S 4 ~ ~~. ks oY 0 EE A E— a TS 0 1 2 months
VT is an automated HIV infection screening test (VIDAS HIV DUO).
VT<0.25 = negative, VT comprised between 0.25-0.35= limited positive,
VT>0.35 = positive.
The results obtained show that the administration by the oral route of
Composition 1 to HIV-AIDS patients causes a significant reduction in the presence of the antigen P24 of HIV-1 and the anti-HIV1 and anti-HIV2 immunoglobulins G in the serum of the patients. The results obtained also show a significant remission in the clinical effects of HIV-AIDS opportunistic diseases. These results suggest that the treatment of the HIV-AIDS patients with Composition 1 causes a stimulation of the immune defences, and a reduction in the side effects of the infection of the HIV-AIDS virus.
Claims (7)
1. Pharmaceutical composition containing as active ingredient at least one . 5s extract of at least one gramineous plant, mixed with at least one extract of at least ) one rutaceous herb, mixed with at least one extract of at least one pteridophyte.
2. Composition according to claim 1, characterized in that it is intended to stimulate the immune defences. 10
3. Composition according to claim 2, characterized in that it is intended to stimulate immune defences weakened by the disease HIV-AIDS.
4. Composition according to claim 1, characterized in that it is intended to be used as an antibacterial or antiviral medicament.
5. Composition according to claim 1, characterized in that it is intended to be used as an antifungal.
6. Composition according to one of the preceding claims, characterized in Bb © that said extracts are plant material originating: 1) from the family of the ~~ gramineous plants, from a paspalum genus, more particularly the paspalum conjugatum species, 2) from the family of the rutaceous herbs, from a fagara genus, more particularly the fagara heitzii species, 3) from the family of the pteridophytes, from a cyathea genus, more particularly the cyathea aethiopica species.
7. Composition according to claim 6, characterized in that said extracts are extracts of paspalum conjugatum, fagara heitzii and cyathea aethiopica.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0310162A FR2859107B1 (en) | 2003-08-26 | 2003-08-26 | USE OF THE EXTRACTS OF A GRAMINEE, A RUTACEE AND A PIERIDOPHYTE IN A PHARMACEUTICAL COMPOSITION WITH ANTIVIRAL, ANTIBACTERIAL, ANTIFUNGAL ACTIVITY AND ALSO INTENDED TO STIMULATE IMMUNE DEFENSES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200604983B true ZA200604983B (en) | 2007-09-26 |
Family
ID=34130597
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200604983A ZA200604983B (en) | 2003-08-26 | 2006-06-19 | Pharmaceutical composition which can be used in particular as an antiviral, antibacterial and for stimulating the immune defences |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1675605B1 (en) |
| AT (1) | ATE391511T1 (en) |
| DE (1) | DE602004013034T2 (en) |
| EA (1) | EA009393B1 (en) |
| FR (1) | FR2859107B1 (en) |
| WO (1) | WO2005021019A1 (en) |
| ZA (1) | ZA200604983B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3021224B1 (en) * | 2014-05-26 | 2017-11-17 | Henri Charles Ainadou | PHYTOMEDICAMENT FOR HIV |
| FR3021871B1 (en) * | 2014-06-10 | 2018-07-13 | Aliou Mamadou Balde | COMPOSITION BASED ON ANTHOSTEMA SENEGALENSE AS A DRUG AGAINST AIDS |
| FR3113586A1 (en) | 2020-08-29 | 2022-03-04 | Bruno Eto | New therapeutic use of Fagaricin as a medicine to treat stenoxene haemoprotozoosis in tropical countries |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE92765T1 (en) * | 1989-02-06 | 1993-08-15 | Chiba Flour Milling | LIMULUSTEST POSITIVE PLANT GLYCOLIPID AND METHOD OF STIMULATING THE IMMUNE SYSTEM OF AN ANIMAL. |
| EP0503208A1 (en) * | 1991-03-08 | 1992-09-16 | Maracuyama International, S.A. | Procedure for obtaining a natural water-soluble extract from the leaves and/or rhizomes of various immunologically active ferns |
| US5837257A (en) * | 1996-07-09 | 1998-11-17 | Sage R&D | Use of plant extracts for treatment of HIV, HCV and HBV infections |
| JP3851829B2 (en) * | 2002-02-28 | 2006-11-29 | 株式会社ノエビア | Skin preparation for the purpose of increasing scattered light on the skin surface |
-
2003
- 2003-08-26 FR FR0310162A patent/FR2859107B1/en not_active Expired - Fee Related
-
2004
- 2004-08-26 DE DE602004013034T patent/DE602004013034T2/en not_active Expired - Lifetime
- 2004-08-26 EP EP04786353A patent/EP1675605B1/en not_active Expired - Lifetime
- 2004-08-26 AT AT04786353T patent/ATE391511T1/en not_active IP Right Cessation
- 2004-08-26 WO PCT/FR2004/002191 patent/WO2005021019A1/en active IP Right Grant
- 2004-08-26 EA EA200600466A patent/EA009393B1/en not_active IP Right Cessation
-
2006
- 2006-06-19 ZA ZA200604983A patent/ZA200604983B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005021019A1 (en) | 2005-03-10 |
| EA009393B1 (en) | 2007-12-28 |
| EP1675605A1 (en) | 2006-07-05 |
| FR2859107A1 (en) | 2005-03-04 |
| EA200600466A1 (en) | 2006-08-25 |
| EP1675605B1 (en) | 2008-04-09 |
| FR2859107B1 (en) | 2008-04-18 |
| DE602004013034D1 (en) | 2008-05-21 |
| ATE391511T1 (en) | 2008-04-15 |
| DE602004013034T2 (en) | 2009-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11166998B2 (en) | Eurycoma longifolia extract and its use in enhancing and/or stimulating immune system | |
| CN101720226B (en) | Aloe preparation for skin enhancement | |
| Deharo et al. | In vitro immunomodulatory activity of plants used by the Tacana ethnic group in Bolivia | |
| WO2003099309A1 (en) | Active fraction having anti-cancer and anti-metastasis isolated from acanthopanax species and fruits | |
| US20110250226A1 (en) | Composition containing extracts of fuscoporia obliqua, ganoderma lucidum and phellinus linteus for promoting the proliferation of hematopoietic stem cells | |
| ZA200506723B (en) | Composition for treating hepatitis C | |
| KR20160050108A (en) | Compositions for Improving Oral Hygiene comprising extracts derived from natural materials and Uses Thereof | |
| US20070248619A1 (en) | New pharmaceutical composition from natural materials for regulating immunity, its preparation method and use | |
| Ita et al. | Haematopoietic properties of ethanolic leaf extract of ageratum conyzoides (goat weed) in albino rats. | |
| CN101267859A (en) | A pharmaceutical composition useful for the treatment of prostate cancer | |
| ZA200604983B (en) | Pharmaceutical composition which can be used in particular as an antiviral, antibacterial and for stimulating the immune defences | |
| WO1994018993A1 (en) | Therapeutic herbal composition | |
| Barrett | Echinacea: A Safety Review. | |
| AU760967B2 (en) | Herbal composition for the prophylaxis and treatment of AIDS | |
| KR20050047579A (en) | Bone disease drug composition using herb medicines | |
| WO2004112692A2 (en) | Therapeutic herbal compositions | |
| EP2680924B1 (en) | A novel herbal composition for the treatment of kidney stone and other urinary tract disorders | |
| WO1995008318A2 (en) | Medicinal substance with anti-infection properties and for use in the treatment of infertility and protection of pregnancy | |
| US7160561B2 (en) | Herbal composition and method of treating HIV infection | |
| US20040258712A1 (en) | Herbal composition containing sea salt | |
| Abue et al. | Using African alternative medicine to curb Covid-19: A case study of SAAAB, SAABFAT6, and SAABMAL HERBAL SUPPLEMENTS | |
| JP2008247797A (en) | Preventing and treating agent of adult t cell leukemia, and pharmaceutical composition of the same | |
| KR20030089253A (en) | A composition with enhanced immunomodulation and anti-cancer activity | |
| CN100443093C (en) | AIDS treating medicine | |
| WO2005092356A1 (en) | A novel herbal composition for treating hiv/aids and fungal infections secondary to hiv |